Senior testis cancer doc. Founder testicular cancer commons, PI S1823, mentor of youngsters, father of farmers. Opinions my own
Portland, Oregon
Joined June 2009
- Tweets1.3K
- Following468
- Followers835
- Likes24
Urgent cisplatin-based chemotherapy beginning today without orchiectomy. If HCG is massively elevated, many centers would give 3 days of EP and hold for a bit and resume with 5 day course once bleeding risk is past. I council such patients that they may end up in ICU intubated
Almost as bad as Or-E Gone. My own from my youth was the word "misled" which I pronounced in my head as my-seld. I knew it had a bad connotation, but not exactly how
JCO Comments and Controversies piece out. Provides rationale for PRESTIGE and MAGESTIC trials to come.
Thanks @UroAlsyouf @siadaneshmand @LuciaNappi4
DOI: 10.1200/JCO.22.02002
@siadaneshmand is stepping out on me with different organ! However, per usual, he's making high-level, multi-front impacts on management of the bladder cancer as well as TC. Congrats on a memorable AUA and keep up the good work
Case for pRPLND as chemo-sparing approach in CSII NS becoming stronger. @moosemousa @RHamiltonUrol #AUA2023 PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR METASTATIC NONSEMINOMATOUS GERM CELL TUMOR:
@LuciaNappi4 ASCO presentation of long f/u BCC pilot will be a forme fruste of S1823 which will also be presented in the Trials in Progress session as well. @SupportingSWOG
Testis cancer oral abstracts ASCO pick up nicely on two emerging likely practice changing themes. miR371 (@LuciaNappi4) and primary RPLND in early regional seminoma (T. Tandstad). Can't wait
Well. . . This is a bit awkward. ChatGPT appears to be as good at poetry as it is at understanding clinical trial design, conduct, actual patient impact and cogent debate
While not a lot of new information, the article is important in that it reiterates the high baseline of CVD risk factors (with or without cisplatin) for men as they move into their 40s/ 50s. Should have low threshold for management of HTN, dyslipidemia, obesity, energy balance
Not ground breaking but worth reiterating. Chemo for GCT was revolutionary but strive to cure while minimizing exposure to it, legit long term baggage
@Testiscancer @siadaneshmand @AdityaBagrodia @drphil_urology ascopubs.org/doi/full/10.120…
Took Bard out for a spin. Not so impressive. Could not stage testis cancer and could not identify Larry Einhorn. Needs some work
Notified that S1823 will be presented as a poster in the Trials in Progress section #ASCO23. @SWOG @supportingSWOG @siadaneshmand, @uroegg,@nabiladra @LuciaNappi4,@RHamiltonUrol @AdityaBagrodia and Andrea Harzstark, SWOG biostats and the over 700 pts enrolled
Nice AUA abstract by Candelas-Gomez, Hamilton, Jewett et al re Canadian 2nd opinion in GCT. Mirrors England SWENTOTECA German efforts at hub and spoke care delivery
Remember this is PFS or TFS NOT OS which is 100%
🧐 First multi-institutional #ClinicalTrial details efficacy of retroperitoneal lymph node dissection in early metastatic #Seminoma ➡️ fal.cn/3x6AP #JCO #surgonc #tscsm @siadaneshmand @GU_Bigwhacks
Well, we will have at least one oral presentation at big #ASCO2023. Magnifico! @LuciaNappi4
AUA Abstracts are out. Expanding data sets for surgical management of CSII GCT @siadaneshmand, USC superstar young urologists and the whole network
Emerging Clinical Decision-Making Tools in Clinical Stage I and IIA/B Germ Cell Tumors—What Are the Targets? dailynews.ascopubs.org/do/em…
Emerging Clinical Decision-Making Tools in Clinical Stage I and IIA/B Germ Cell Tumors—What Are the Targets?
ASCO Daily News piece out today with colleagues @LuciaNappi4 @siadaneshmand and C. Kollmannsberger
Emerging Clinical Decision-Making Tools in Clinical Stage I and IIA/B Germ Cell Tumors—What Are the Targets? dailynews.ascopubs.org/do/em…
I am glad we persisted with @ASCO_JCO. The most important audience for ascopubs.org/doi/10.1200/JCO… probably is medical oncologists who often are the gatekeepers in the US for early stage patients. Chemo-lite options for young pts are always welcome
